risk and the procedure can be tolerated by older patients. At this time there is no evidence that the results of allogeneic stem cell transplantation are better than autologous We sought to determine whether circulating tumor cells in the blood stem cell harvest from patients with mulstem cell transplantation for patients with multiple myeloma. 1 Recently, autologous transplantation was demontiple myeloma are associated with a shortened diseasefree survival. Prospective analysis was performed in 33 strated to be superior to conventional chemotherapy for multiple myeloma patients who were previously untreated patients of blood obtained at leukapheresis for future transplantation. An immunofluorescence microscopy and younger than age 65 years. In retrospective studies 4 of patients with multiple myeloma and primary resistant disease with an expected median surcells/l, seven have relapsed, with a median relapse-free survival of 22.5 months (P = 0.008). Patients with circulvival of Ͻ12 months, the use of myeloablative therapy with bone marrow transplantation resulted in significant proating plasma cells showed a trend toward shorter overall survival (P = 0.078). In a multivariate analysis using longation of median survival. Intensive cytoreductive therapy using autologous bone marrow has achieved a high the bone marrow plasma cell labeling index and ␤ 2 -microglobulin, the absolute number of plasma cells in proportion of complete responses.
Summary:
risk and the procedure can be tolerated by older patients. At this time there is no evidence that the results of allogeneic stem cell transplantation are better than autologous We sought to determine whether circulating tumor cells in the blood stem cell harvest from patients with mulstem cell transplantation for patients with multiple myeloma. 1 Recently, autologous transplantation was demontiple myeloma are associated with a shortened diseasefree survival. Prospective analysis was performed in 33 strated to be superior to conventional chemotherapy for multiple myeloma patients who were previously untreated patients of blood obtained at leukapheresis for future transplantation. An immunofluorescence microscopy and younger than age 65 years. In retrospective studies 4 of patients with multiple myeloma and primary resistant disease with an expected median surcells/l, seven have relapsed, with a median relapse-free survival of 22.5 months (P = 0.008). Patients with circulvival of Ͻ12 months, the use of myeloablative therapy with bone marrow transplantation resulted in significant proating plasma cells showed a trend toward shorter overall survival (P = 0.078). In a multivariate analysis using longation of median survival. Intensive cytoreductive therapy using autologous bone marrow has achieved a high the bone marrow plasma cell labeling index and ␤ 2 -microglobulin, the absolute number of plasma cells in proportion of complete responses. 5 Although reconstitution of normal hematopoiesis is achithe stem cell harvest achieved borderline significance for predicting relapse-free survival (P = 0.057). In conevable by using bone marrow, it is a theoretically unappealing source of stem cells in multiple myeloma. Virtually all clusion, increased monoclonal plasma cells in the blood stem cell harvest are associated with a shortened patients who come to transplant have a detectable population of clonal plasma cells in the bone marrow, and these relapse-free survival. This does not necessarily indicate that the circulating plasma cells were responsible for cells can be a potential source of relapse. It is known that hematopoietic stem cells are circulating in the blood of relapse. These results, however, have implications with regard to the timing of obtaining blood stem cells for patients with malignant disease, and they can be collected in satisfactory numbers. The stem cells are capable of fully patients who are candidates for ablative chemotherapy. Keywords: circulating tumor cells; multiple myeloma; reconstituting hematopoiesis in the recipients of supralethal chemoradiotherapy. 6 The appearance of blood progenitor peripheral blood stem cell transplantation cells with multilineage potential has been demonstrated after priming with high-dose cyclophosphamide as well as with the growth factors granulocyte (G) or granulocyteIntensive chemoradiotherapy followed by hematopoietic monocyte (GM) colony-stimulating factor (CSF). stem cell reconstitution is being applied increasingly for Blood as a source of stem cells has the advantage of younger patients with multiple myeloma. The use of alloeasy accessibility and availability. Theoretically, the risk of geneic stem cells is limited because patients have a median tumor cell contamination in the harvested peripheral blood age of 64 years at diagnosis of multiple myeloma, and the may be lower than that in the bone marrow aspirates of frequency of early deaths associated with transplant-related patients with multiple myeloma. In four to six apheresis complications remains significant. Autologous stem cell procedures, a median number of 160 × 10 6 CD34 + /33 − cells transplantation has wider applicability in patients with mulcan be obtained. The absolute number of pluripotent precurtiple myeloma because graft-versus-host disease is not a sors is therefore not lower than that obtained in bone marrow. 7 Autologous blood stem cell transplantation has been applied to the treatment of patients with multiple myeloma, patients with high-risk multiple myeloma, the use of blood progenitor cell rescue after ablative therapy has produced Ͼ100 mg/24 h. Patients with nonsecretory multiple myeloma were not eligible. Patients with plasma cell leukemia, a median overall survival of 41 months in patients with a high labeling index and poor prognosis myeloma. 9 a creatinine concentration of Ͼ2 mg/dl, or a bilirubin concentration of Ͼ2 mg/dl were excluded from participation. Unfortunately, malignant cells are present in small numbers in the blood of some patients with multiple myeloma, The patients were required to have adequate pulmonary function (diffusing capacity of the lung for carbon monoxas determined by various techniques.
10-13 They have also been documented to contaminate blood stem cell harvest ide Ͼ50% and 1-s forced expiratory volume Ͼ60%) and an echocardiographic ejection fraction of Ͼ50%. Transplant products.
14 The purpose of this study was to determine whether blood stem cell harvest products contaminated with eligibility required an age р65 years and an Eastern Cooperative Oncology Group performance status of 0 to 2. monoclonal plasma cells were associated with a shorter time to progression than those that were not.
Patients did not have transplants until they had relapsed.
Patients who failed to respond to initial therapy underwent transplantation immediately after failing to respond to initial chemotherapy. Patients were treated with three Patients and methods cycles of vincristine, doxorubicin, and dexamethasone chemotherapy followed by stem cell harvest. Patients then Patients were studied who had multiple myeloma and underwent blood stem cell harvest between May 1989 and resumed standard chemotherapy and had transplants at progression. June 1994. All patients gave written informed consent, and the protocol was approved by the Institutional Review Board of Mayo Foundation. The blood mononuclear cells
Statistical methods examined for monoclonal plasma cells represented an aliquot of the apheresis product (n = 29) or a blood sample
Curves showing freedom from progression and overall (n = 8) taken at the time of apheresis.
survival were calculated by the Kaplan-Meier method.
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The number of monoclonal plasma cells was measured Progression was defined as a 50% increase in the serum as previously described on mononuclear cells from the monoclonal protein level from the lowest level after transblood. 15 In all but two cases, the mononuclear cells were plantation. Any new radiographic bone lesions were conavailable directly from the apheresis product; in the two sidered progression without regard to changes in M cases in which only a peripheral vein venipuncture sample protein level. Multivariate analysis was done by using the was available, the mononuclear cells were isolated by cenproportional-hazards model of Cox.
19 trifugation over Ficoll-Hypaque. The mononuclear cell samples were depleted of T cells by use of an anti-CD2 monoclonal antibody conjugated to magnetic beads Results (DynaBeads; Dynal Corporation, Great Neck, NY, USA). Cytocentrifuge slides were made, air dried, and fixed for 10 min in 95% ethanol. Separate slides were stained with A total of 38 patients underwent transplantation during the study period. One patient was excluded because no sample antibody to kappa and lambda light chain reagents that were conjugated to fluorescein isothiocyanate. This technique was obtained from the leukapheresis product for immunofluorescence microscopy. Four other patients died before identifies monoclonal plasma cells by their classic morphology and visual documentation, in situ of cytoplasmic day +25 after their transplant (two infection, one venoocclusive disease, one acute renal failure). These patients immunoglobulin light chain restriction. Photomicrographs of typical cases have been previously published. 15, 16 all died of transplant-related complications and were not evaluable for response and relapse. This left 33 patients Additional studies have shown that when blood monoclonal plasma cells are detected by this immunofluorescence with available samples who survived beyond day +25. The characteristics of these patients are given in Table 1 . All microscopy technique, monoclonal CD38 + CD45 − /dim + light chain restricted cells are detected by three-color flow patients had advanced multiple myeloma, and none were in a stable plateau phase at transplantation. The median durcytometry 17 and clonal cells are detected by a polymerase chain reaction technique using an allele-specific oligonucleation of disease before transplant was 23 months. Duration of myeloma was measured from first exposure to chemootide made from the bone marrow myeloma cells. 16 The absolute number of monoclonal plasma cells was therapy and not from original histologic diagnosis. Patients had failed a median of two regimens before transplant. calculated as follows: total leukocyte count × percent mononuclear cells × percent immunoglobulin-positive Two-thirds of the patients had an elevated ␤ 2 -microglobulin value (Ͼ2.7 g/ml) and 59% had bone marrow plasma cells × percent plasma cells = monoclonal plasma cells × 10 6 /l. The leukocyte count and percent mononuclear cells of у30% at the time of transplantation. Sixty-three percent of patients had an elevated bone marrow plasma cells were determined in a blood sample on the day of the study. When more than one apheresis sample was available cell labeling index (у0.8%). Regimens that included intravenous administration of melphalan 140 mg/m 2 and total for analysis of tumor cell contamination, the highest single value obtained was used for that patient in the analysis of body radiation to 12 Gy were administered in 29 of the 33 patients. One patient who had extensive thoracic spine relapse-free and overall survival.
The diagnosis of multiple myeloma was confirmed by radiation could not receive total body radiation and was given melphalan 200 mg/m 2 . Three patients received cyclotraditional methods of bone marrow plasmacytosis and an M component in the serum of Ͼ1 g/dl or in the urine of phosphamide-based conditioning (120 mg/kg) because of 339 Table 1 Characteristics of meloma patients undergoing stem cell transplantation were a significant predictor (P Ͻ 0.02) of relapse-free sur- A 4 vival. The analysis also used the number of blood plasma A 3 cells as a categorical variable. Figure 1 shows the relapse- Although this study demonstrated that the presence of monoclonal plasma cells in the blood is associated with numbers of circulating plasma cells showed a trend toward improved overall survival (P = 0.078). There was no differearly relapse, it does not prove that the blood plasma cells are the cause of the relapse. Tumor cells are most comence in relapse-free survival between the 17 patients who had transplants after relapsing on chemotherapy and the 12 monly found in the blood during active disease, 15,23,24 and the fact that tumor cells in the harvest predict early relapse who had transplants after relapse off chemotherapy (P Ͼ 0.5).
may be more of a reflection of the overall status of the patient's multiple myeloma at the time of relapse. There are two ways to learn more about the role of tumor cells Discussion in the harvest product in producing relapse. The first and most ideal method would be to mark the collected tumor Clonal cells can be detected in the blood of most patients with active multiple myeloma by using various techcells with a safety modified retrovirus and subsequently detect the virally marked cells in bone marrow after niques.
10,11,15,20-24 Similar studies 14,25-31 on the blood stem cell harvest products from patients with multiple myeloma relapse. 33, 34 This has been demonstrated in patients after autologous bone marrow transplant for acute and chronic have recently demonstrated that these products are frequently contaminated with malignant cells. Although these myelogenous leukemia. 35, 36 Clues regarding the importance of these contaminating cells can also be learned from clinistudies have documented malignant cells in the harvest product, it was not known whether this would shorten relapsecal trials of blood stem cell transplants in multiple myeloma where stem cells are harvested after the disease has free survival. The study by Dreyfus et al 31 suggested that there was no effect of the presence of tumor cells in the responded and the actual transplant may be performed months or years later when the patient's condition is in harvest product on response to transplant therapy; however, an early analysis of relapse-free survival indicates four of early relapse. Ideally, a prospective randomized trial using purged and unpurged stem cell products would be required eight patients with contaminated harvests have relapsed compared with only two of 13 with harvests negative for to address absolutely the relevance of circulating stem cells. The current study contains some design drawbacks. of post-transplant salvage regimens, which can be quite effective, in relapsing patients. 32 Ideally, all patients should have been conditioned identically to reduce variations attributable to induction efficacy. The cutoff number of circulating plasma cells was chosen retrospectively for prognostic purposes. Analysis of It has not been demonstrated that differences in conditioning change patient outcome. A second design flaw involves the number of circulating plasma cells was significant as a continuous variable but was also analyzed as a discrete the variable mobilization regimens used to obtain stem cells. It has been demonstrated 37 that stem cells mobilized variable for display purposes. In a prior study 15 we chose an arbitrary cutoff value of 3 × 10 6 cells/l in discriminating after GM-CSF and high-dose cyclophosphamide have increasing numbers of plasma cells after day 5 of collecactive from inactive myeloma. Also in the prior study, 67% had у3 × 10 6 plasma cells/l, whereas in the current study tion. We found that plasma cells Ͼ0.2 × 10 6 /l were present in 12 of 27 patients mobilized with a growth factor and this occurred in only 27%. Kaplan-Meier analysis of circulating plasma cells using the 3 × 10 6 cells/l cutoff still three of six not receiving a growth factor (P = 0.8, 2 ). This variability did not impact on the outcome. revealed a significant impact on relapse-free survival (logrank test P Ͻ 0.03). Seven of the patients had between
The technique used to detect tumor cells in this study was immunofluorescence microscopy. This technique has 0.2 and 3 × 10 6 circulating plasma cells/l. We believe the reason for the differences between the the advantage of microscopic identification of monoclonal plasma cells by their classic morphology along with visual two studies relates to differences in the two populations. In the prior study, patients with active disease had samples confirmation that these cells were monoclonal for cytoplasmic light chain. Its disadvantage is that tumor cells without measured immediately and there was no limit on the number of failed chemotherapy regimens. In the current study, plasma cell morphology will not be detected; therefore, although the levels of contamination reported in this study patients had a median of two prior regimens. Moreover, in preparation for transplantation, patients in this study are significant in that they are associated with a short relapse-free survival, they should be viewed as a minimum received three cycles of vincristine, doxorubicin, and dexamethasone before sample analysis. We assume that the level of contamination. It is likely that molecular techniques would have detected higher levels of contamination but it pretransplant chemotherapy would have had a significant effect on lowering the numbers of circulating plasma cells is not known that this increased level of detection would be clinically useful in predicting relapse-free or overall before stem cell collection, given the high response rates of relapsed patients to vincristine, doxorubicin, and survival.
One cannot ignore the possibility that the circulating dexamethasone chemotherapy.
